EPTINEZUMAB FOR PREVENTION OF CHRONIC MIGRAINE (CM): RESULTS OF 2 INFUSIONS IN THE PHASE 3 PROMISE-2 (PREVENTION OF MIGRAINE VIA INTRAVENOUS EPTINEZUMAB SAFETY AND EFFICACY-2) TRIAL

被引：0
|
作者：
Ashina, M. [1 ]
Goadsby, P. J. [2 ]
Lipton, R. B. [3 ]
Azimova, J. [4 ]
Winner, P. [5 ]
Schaeffler, B. [6 ]
Biondi, D. [6 ]
Bhattacharya, S. [6 ]
Smith, J. [7 ]
Cady, R. [6 ]
机构：
[1] Univ Copenhagen, Rigshosp Glostrup, Danish Headache Ctr, Copenhagen, Denmark
[2] Kings Coll London, NIHR Wellcome Trust Kings Clin Res Facil, London, England
[3] Albert Einstein Coll Med, Montefiore Headache Ctr, Bronx, NY 10467 USA
[4] Univ Headache Clin, Moscow, Russia
[5] Palm Beach Headache Ctr, Premiere Res Inst, W Palm Beach, FL USA
[6] Alder BioPharmaceut Inc, Bothell, WA USA
[7] Alder BioPharmaceut Inc, Dublin, Ireland
来源：
CEPHALALGIA | 2018年 / 38卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
MTIS2018-0
引用
收藏
页码：84 / 85
页数：2
相关论文
共 50 条
  • [21] Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2
    Martin, V.
    Nagy, A. J.
    Janelidze, M.
    Giorgadze, G.
    Hirman, J.
    Cady, R.
    Mehta, L.
    Buse, D. C.
    JOURNAL OF HEADACHE AND PAIN, 2021, 22 (SUPPL 1): : 17 - 17
  • [22] Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2
    Martin, V.
    Nagy, A. J.
    Janelidze, M.
    Giorgadze, G.
    Hirman, J.
    Cady, R.
    Mehta, L.
    Buse, D. C.
    CEPHALALGIA, 2021, 41 (1_SUPPL) : 25 - 25
  • [23] Baseline Population Characteristics of PROMISE-2: A Phase 3, Randomized, Double-blind, Placebo-Controlled Study of Eptinezumab for Prevention of Chronic Migraine
    Spierings, E. L. H.
    Khan, A.
    Cady, R.
    Schaeffler, B.
    Bhattacharya, S.
    Biondi, D.
    Hirman, J.
    Smith, J.
    HEADACHE, 2018, 58 : 98 - 99
  • [24] Impact of Baseline Characteristics on the Efficacy and Safety of Eptinezumab in Patients With Migraine: Subgroup Analyses of PROMISE-1 and PROMISE-2
    Martin, Vincent
    Nagy, A. Jim
    Janelidze, Marina
    Giorgadze, Gvantsa
    Hirman, Joe
    Cady, Roger
    Mehta, Lahar
    Buse, Dawn C.
    CLINICAL THERAPEUTICS, 2022, 44 (03) : 389 - 402
  • [25] Impact of baseline characteristics on the efficacy and safety of eptinezumab in patients with migraine: Subgroup analyses of PROMISE-1 and PROMISE-2
    Martin, V. T.
    Nagy, A. J.
    Janelidize, M.
    Giorgadze, G.
    Hirman, J.
    Cady, R.
    Mehta, L.
    Buse, D. C.
    HEADACHE, 2021, 61 : 129 - 130
  • [26] Migraine-Free Months in Patients with Episodic or Chronic Migraine Treated with Eptinezumab: Results from the PROMISE-1 and PROMISE-2 Trials
    Winner, P. K.
    McAllister, P.
    Cady, R.
    Snapinn, S.
    Hirman, J.
    Kassel, E.
    HEADACHE, 2019, 59 : 162 - 162
  • [27] Eptinezumab Achieved Meaningful Reductions in Migraine Activity Within 24 Hours That Were Sustained Through Week 12: Results From PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy-1) Phase 3 Trial
    Smith, Timothy
    Biondi, David
    Berman, Gary
    Freeman, Marshall
    Hirman, Joe
    Kassel, Eric
    NEUROLOGY, 2018, 90
  • [28] Migraine Activity Reductions with Eptinezumab Were Associated with Improvements in Short-Form Health Survey Scores Most Affected by Migraine: Results from Phase 3 PROMISE-2 Trial in Chronic Migraine
    Saper, J.
    Diamond, M.
    Huffman, C.
    Biondi, D.
    Bhattacharya, S.
    Hirman, J.
    Cady, R.
    HEADACHE, 2018, 58 : 81 - 82
  • [29] Efficacy, tolerability, and safety of eptinezumab in patients with a dual diagnosis of chronic migraine and medication-overuse headache: Subgroup analysis of PROMISE-2
    Diener, Hans-Christoph
    Marmura, Michael J.
    Tepper, Stewart J.
    Cowan, Robert
    Starling, Amaal J.
    Diamond, Merle L.
    Hirman, Joe
    Mehta, Lahar
    Brevig, Thomas
    Sperling, Bjorn
    Cady, Roger
    HEADACHE, 2021, 61 (01): : 125 - 136
  • [30] Eptinezumab Infusion Associated with Meaningful Reductions in Daily Migraine Activity on Day 1 and Over Weeks 1 Through 4 in Patients with Frequent Episodic Migraine: Results of the PROMISE-1 (PRevention Of Migraine via Intravenous eptinezumab Safety and Efficacy 1) Trial
    Cady, Roger
    Smith, Timothy
    Biondi, David
    Berman, Gary
    Freeman, Marshall
    Hirman, Joe
    Kassel, Eric
    CEPHALALGIA, 2017, 37 : 341 - 342
12345